Results 161 to 170 of about 8,213 (210)

Amikacin exposure in MDR-TB patients in Uganda: Revisiting old drugs in a new era of resistance - A pharmacokinetic assessment. [PDF]

New Microbes New Infect
Hongler J, Haller S, Adakun AS, Lutz N, Buzibye A, Kälin M, Castelnuovo B, Sekaggya-Wiltshire C, Abongomera G, Jetter A, Fehr J.   +10 more
europepmc   +1 more source

Comparative Study of the Quality of Life of Patients With Ototoxicity Due to Platinum-Based Chemotherapy, With Hearing Aid Versus Those Without: Study Protocol for a Randomized Pilot Study-The PROTOTOX Study.

JMIR Res Protoc
Mastronicola R, Kayser E, Fernandez Y, Dolivet G.   +3 more
europepmc   +1 more source

Sex differences in response to kanamycin-induced ototoxicity in C57BL/6 J mice. [PDF]

Sci Rep
Smith-Cortinez N, Straatman LV, Hendriksen FGJ, Stokroos RJ, Versnel H.   +4 more
europepmc   +1 more source

Platinum-induced ototoxicity and hearing impairment in children and adolescents. [PDF]

Drugs Context
Romano A, Attinà G, Maurizi P, Talloa D, Mastrangelo S, Ruggiero A.   +5 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

The importance of high-tone audiometry in monitoring for ototoxicity

Archives of Oto-Rhino-Laryngology, 1985
Early detection of ototoxicity is of vital importance in cases in which ototoxic drugs are administered. Ototoxicity as a result of cis-platinum administration is well documented. Auditory damage may be reduced by changes in dose, drugs or methods of treatment. As ototoxicity appears to be most pronounced in the higher frequencies of sound, any changes
Tange, R. A., Dreschler, W. A., van der Hulst, R. J.   +2 more
openaire   +5 more sources

Audiologic Monitoring for Ototoxicity

Otolaryngologic Clinics of North America, 1993
In summary, the clinician has a variety of protocols available for monitoring ototoxicity. Depending on the patient's risk factors and ability to be tested, the protocol for a given patient may vary. A flow chart reflecting some of the possible decisions and options is presented in Figure 1.
K C, Campbell, J, Durrant
openaire   +2 more sources

Audiometric monitoring of cis-platinum ototoxicity

Gynecologic Oncology, 1983
A prospective study was performed on 37 patients receiving 50 mg/m2 of cis-platinum every 3 to 4 weeks. These patients received a baseline audiogram evaluation and subsequent testing before each dose. Ototoxicity was noted to occur in 46% of the patients during therapy. Fourteen percent of this group showed a hearing loss in the speech frequency range.
R L, Brown, R C, Nuss, R, Patterson, J, Irey   +3 more
openaire   +2 more sources

Drug-Induced Ototoxicity: Diagnosis and Monitoring

Drug Safety, 2018
Ototoxicity diagnosis and management has historically been approached using a variety of methods. However, in recent years a consensus on useful and practical approaches has been developed through clinical guidelines of the American Speech Language Hearing Association, the American Academy of Audiology, and multiple clinical trials published in peer ...
Kathleen C M, Campbell, Colleen G, Le Prell   +1 more
openaire   +2 more sources